209 related articles for article (PubMed ID: 33780728)
1. Generation of two induced pluripotent stem cell lines from blood cells of a prostate cancer patient carrying germline mutation in CHEK2.
Liu R; Qian K; Xiao Y; Jiang W
Stem Cell Res; 2021 May; 53():102299. PubMed ID: 33780728
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
Wu Y; Yu H; Zheng SL; Na R; Mamawala M; Landis T; Wiley K; Petkewicz J; Shah S; Shi Z; Novakovic K; McGuire M; Brendler CB; Ding Q; Helfand BT; Carter HB; Cooney KA; Isaacs WB; Xu J
Prostate; 2018 Jun; 78(8):607-615. PubMed ID: 29520813
[TBL] [Abstract][Full Text] [Related]
3.
Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
[TBL] [Abstract][Full Text] [Related]
4. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
5. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
[TBL] [Abstract][Full Text] [Related]
6. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
[TBL] [Abstract][Full Text] [Related]
7. Mutations in CHEK2 associated with prostate cancer risk.
Dong X; Wang L; Taniguchi K; Wang X; Cunningham JM; McDonnell SK; Qian C; Marks AF; Slager SL; Peterson BJ; Smith DI; Cheville JC; Blute ML; Jacobsen SJ; Schaid DJ; Tindall DJ; Thibodeau SN; Liu W
Am J Hum Genet; 2003 Feb; 72(2):270-80. PubMed ID: 12533788
[TBL] [Abstract][Full Text] [Related]
8. The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study.
Alorjani M; Aburub M; Al-Trad B; Hamad MA; AbuAlarja M; Bashir SA; Al-Batayneh K; Zoubi MA
Med Arch; 2023 Feb; 77(1):8-12. PubMed ID: 36919124
[TBL] [Abstract][Full Text] [Related]
9. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2.
Hinić S; Cybulski C; Van der Post RS; Vos JR; Schuurs-Hoeijmakers J; Brugnoletti F; Koene S; Vreede L; van Zelst-Stams WAG; Kets CM; Haadsma M; Spruijt L; Wevers MR; Evans DG; Wimmer K; Schnaiter S; Volk AE; Möllring A; de Putter R; Soikkonen L; Kahre T; Tooming M; de Jong MM; Vaz F; Mensenkamp AR; Genuardi M; Lubinski J; Ligtenberg M; Hoogerbrugge N; de Voer RM
Genet Med; 2024 May; 26(5):101101. PubMed ID: 38362852
[TBL] [Abstract][Full Text] [Related]
10. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations.
Zhang M; Venkateshappa R; Li A; Fowler MB; Telli ML; Wu JC
Stem Cell Res; 2023 Dec; 73():103246. PubMed ID: 37951143
[TBL] [Abstract][Full Text] [Related]
12. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
13. Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants.
Zhang M; Liu W; Li A; Htet MH; Yu R; Telli ML; Wu JC
Stem Cell Res; 2023 Oct; 72():103219. PubMed ID: 37816281
[TBL] [Abstract][Full Text] [Related]
14. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
[TBL] [Abstract][Full Text] [Related]
15. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Clinical and Genetic Analysis of
Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192
[TBL] [Abstract][Full Text] [Related]
17. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline
Thibodeau ML; Reisle C; Zhao E; Martin LA; Alwelaie Y; Mungall KL; Ch'ng C; Thomas R; Ng T; Yip S; J Lim H; Sun S; Young SS; Karsan A; Zhao Y; Mungall AJ; Moore RA; J Renouf D; Gelmon K; Ma YP; Hayes M; Laskin J; Marra MA; Schrader KA; Jones SJM
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28514723
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer.
Złowocka E; Cybulski C; Górski B; Debniak T; Słojewski M; Wokołorczyk D; Serrano-Fernández P; Matyjasik J; van de Wetering T; Sikorski A; Scott RJ; Lubiński J
Int J Cancer; 2008 Feb; 122(3):583-6. PubMed ID: 17918154
[TBL] [Abstract][Full Text] [Related]
20. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Hanson H; Astiazaran-Symonds E; Amendola LM; Balmaña J; Foulkes WD; James P; Klugman S; Ngeow J; Schmutzler R; Voian N; Wick MJ; Pal T; Tischkowitz M; Stewart DR;
Genet Med; 2023 Oct; 25(10):100870. PubMed ID: 37490054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
